Treatment optimization for mycobacterial diseases: - Management and outcome of mycobacterial diseases

Research Research programs Treatment optimization for mycobacterial diseases:

Our purpose

We aim to optimize treatment and outcome of mycobacterial diseases, including tuberculosis (TB), the leading infectious disease killer worldwide. In settings where tuberculosis incidence is reducing, opportunistic infections with non-tuberculous mycobacteria (NTM) are emerging.

Goals

See some of the most important goals for this research program.

Listen

Goals

To develop new diagnostic tools to guide personalized treatment.
To develop, redevelop or repurpose drugs that optimize treatment and outcome of mycobacterial diseases.
To implement these diagnostics and drugs into health policy and clinical practice.
To anchor the patient perspective in our research activities.
To build human and infrastructural capacity to empower the research of colleagues abroad.
To attract, educate and train talented young researchers to study mycobacterial diseases.

Research groups contributing to this research program

Global health and infectious diseases

Reinout van Crevel's research group studies patients in Europe, Asia and Africa to understand pathogenesis and to improve clinical management.

Global health economics

Rob Baltussen's research group is active in international health systems research and in particular in health benefit package design, informed by health technology assessment (HTA). In this, the group supports Ministries of Health in a range of low, middle and high income countries.

Systems immunology

Vinod Kumar's research group goal is to exploit the host-pathogen interaction by understanding how our genetic make-up influence patient-specific disease outcome during infection. Infectious agents are one of the major factors involved in shaping our human genome.

Spokesperson(s) for this research program

Spokesperson

prof. dr. Rob Aarnoutse

contact form